ପ୍ରାସୁଗ୍ରେଲ

ପ୍ରାସୁଗ୍ରେଲ
Clinical data
Trade names	Effient, Efient
AHFS/Drugs.com	monograph
MedlinePlus	a609027
data	EU EMA: yes; US DailyMed: Prasugrel;
Pregnancy; category	AU: B1 ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	≥79%
Protein binding	Active metabolite: ~98%
Elimination half-life	~7 h (range 2 h to 15 h)
Excretion	Urine (~68% inactive metabolites); feces (27% inactive metabolites)
Identifiers
	IUPAC name (RS)-5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-; tetrahydrothieno[3,2-c]pyridin-2-yl acetate;
ECHA InfoCard	100.228.719
Chemical and physical data
Formula	C20H20FNO3S
Molar mass	୩୭୩.୪୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)Oc1cc2c(s1)CCN(C2)C(c3ccccc3F)C(=O)C4CC4;
	InChI InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3 ; Key:DTGLZDAWLRGWQN-UHFFFAOYSA-N ;
(verify)

ପ୍ରାସୁଗ୍ରେଲ, ଏକ ବେପାର ନାମ ଏଫିଏଣ୍ଟ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପରକ୍ୟୁଟାନିଅସ କରୋନାରୀ ଇଣ୍ଟରଭେନସନ (PCI) ଚିକିତ୍ସାରେ ଥିବା ତୀବ୍ର କରୋନାରି ସିଣ୍ଡ୍ରୋମ (ACS) ରୋଗୀମାନଙ୍କର ଲୋକମାନଙ୍କ ରକ୍ତ ଜମାଟ ନ ବାନ୍ଧିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ଏହା ଆସ୍ପିରିନ୍ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତସ୍ରାବ ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥ୍ରୋମ୍ବୋଟିକ ଥ୍ରୋମ୍ବୋସାଇଟୋପେନିକ ପୁରପୁରା ଏବଂ ଆଞ୍ଜିଓଇଡେମା ହୋଇପାରେ।^[୨] ଏହା ପି୨ୱାଇ₁₂ (P2Y₁₂ ) ପ୍ଲାଲେଟ୍ ଆଡେନୋସିନ ଡାଇଫସଫେଟ୍ (ADP) - ରିସେପ୍ଟର ଇନହିବିଟର ପ୍ରକାରର ଏକ ପ୍ଲାଟେଲେଟ ଇନହିବିଟର ।^[୨]

୨୦୦୯ ମସିହାରେ ୟୁରୋପ ଏବଂ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୧] ^[୩] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ।^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ୪ ସପ୍ତାହର ଔଷଧ ପ୍ରାୟ ୬ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣ ପାଇଁ ପ୍ରାୟ ୩୦ ଡଲାର ଖର୍ଚ୍ଚ ହୁଏ ।^[୫] ୨୦୨୦ ମସିହାରୁ ଏହା ଆଉ କାନାଡାରେ ଉପଲବ୍ଧ ହେଉନାହିଁ ।^[୬]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Efient". Archived from the original on 26 February 2021. Retrieved 29 October 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "DailyMed - PRASUGREL- prasugrel hydrochloride tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 30 October 2021. Retrieved 29 October 2021.
↑ "Prasugrel Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 February 2021. Retrieved 29 October 2021.
↑ ^୪.୦ ^୪.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 230. ISBN 978-0857114105.
↑ "Prasugrel Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 April 2021. Retrieved 29 October 2021.
↑ Lordkipanidzé, Marie (December 2020). "Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada". CJC Open. 2020. doi:10.1016/j.cjco.2020.11.021. ISSN 2589-790X. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)

[EPAR2021-1] ୧.୦ ^୧.୧ ^୧.୨ "Efient". Archived from the original on 26 February 2021. Retrieved 29 October 2021.

[PI2021-2] ୨.୦ ^୨.୧ ^୨.୨ "DailyMed - PRASUGREL- prasugrel hydrochloride tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 30 October 2021. Retrieved 29 October 2021.

[AHFS2021-3] "Prasugrel Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 February 2021. Retrieved 29 October 2021.

[BNF81-4] ୪.୦ ^୪.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 230. ISBN 978-0857114105.

[5] "Prasugrel Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 April 2021. Retrieved 29 October 2021.

[Lor2020-6] Lordkipanidzé, Marie (December 2020). "Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada". CJC Open. 2020. doi:10.1016/j.cjco.2020.11.021. ISSN 2589-790X. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]